Mark Tuszynski News Today

NurOwn, Brainstorm Cell Therapeutics’ experimental stem cell therapy for ALS, did not win the backing of an independent panel of FDA advisors. Many advisory committee members said they want to see more data from another clinical trial, the same guidance the FDA has given the biotech for nearly three years.

THREE OAKS — A woman is dead and a man was hospitalized Tuesday after fire consumed their home at Lakewood Estates Manufactured Homes, northwest of Three Oaks.

The National Institute on Aging (NIA), part of the National Institutes of Health, has awarded a $5 million grant to researchers at University of California San Diego School of Medicine to conduct a first-in-human Phase 1 clinical trial of a gene therapy for treating Alzheimer's disease (AD) or Mild Cognitive Impairment (MCI), a condition that often precedes full-blown dementia.

First Clinical Trial to Assess Alzheimer’s Gene Therapy Receives $5 Million News_release The National Institute on Aging (NIA), part of the National Institutes of Health, has awarded a $5 million grant to researchers at University of California San Diego School of Medicine to conduct a first-in-human Phase 1 clinical trial of a gene therapy for treating Alzheimer’s disease (AD) or Mild Cognitive Impairment (MCI), a condition that often precedes full-blown dementia. Gene therapy is an exp...

La Jolla permit reviewers approve two home projects and dispute design plan for addition to historic house La Jolla’s Development Permit Review Committee approved plans to add to this property at 5692 Dolphin Place. (Courtesy) Print Two Bird Rock residential projects got the La Jolla Development Permit Review Committee’s approval on the first try during the board’s March 9 meeting. Any preliminary review can be made final by a unanimous vote, which allows the board to make a reco...

First-in-Human Clinical Trial to Assess Gene Therapy for Alzheimer’s Disease UC San Diego researchers will inject harmless virus carrying a restorative gene into participants’ brains, where earlier animal studies suggest it may slow, prevent or reverse progression of the neurological disorder February 18, 2021  |  Scott LaFee News_release Researchers at University of California San Diego School of Medicine have launched a first-in-human Phase I clinical trial to assess the safe...

By Rebekah Gonzalez Feb 23, 2021 The University of San Diego School of Medicine has launched a first-in-human Phase I clinical trial to test the benefits and safety of gene therapy. They are now looking for participants. Researchers are using the trial to see if gene therapy can be used to deliver a key protein (brain-derived neurotrophic factor or BDNF) into the brains of those with Alzheimers disease or Mild Cognitive Impairment, which often leads to dementia. "We found that delivering BDN...

The Phase 1 clinical trial involves a type of gene therapy that will be used for the first time in humans